logo-loader
RedHill Biopharma

RedHill BioPharma lead drug making its way towards FDA approval

RedHill Biopharma (NASDAQ:RDHL) CEO Dror Ben-Asher sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.

The biopharmaceutical company is primarily focused on the development and commercialization of late clinical-stage, proprietary drugs for the treatment of gastrointestinal diseases.

Quick facts: RedHill Biopharma

Price: $7.20

Market: NASDAQ
Market Cap: $204.68 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Great Bear Resources releases more positive drill results...

Great Bear Resources (CVE: GBR) President and CEO Chris Taylor joined Steve Darling from Proactive Vancouver to discuss their latest assay results from the drill program on the Dixie Project in Red Lake.  Taylor discusser the results from the Hinge and Dixie Limb zones and also gave...

18 hours, 49 minutes ago

2 min read